BIOMAT Database Logo BIOMAT Database Logo

[Parkinson disease: clinical, physiopathological and therapeutic aspects]. 1984

W L Sanvito, and J C Villares

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson

Related Publications

W L Sanvito, and J C Villares
[Physiopathological and clinical aspects of Parkinson disease. Current problems].
January 1979, Rivista di neurologia,
W L Sanvito, and J C Villares
Osteogenesis imperfecta: physiopathological, clinical and therapeutic aspects.
January 1981, Basic and applied histochemistry,
W L Sanvito, and J C Villares
[Idiopathic myelofibrosis: clinical, physiopathological and therapeutic aspects].
January 1968, Omnia medica et therapeutica,
W L Sanvito, and J C Villares
Diabetic microangiopathy: physiopathological, clinical and therapeutic aspects.
September 2007, Minerva endocrinologica,
W L Sanvito, and J C Villares
[Hypothyroidism: current clinical, physiopathological and therapeutic aspects].
June 1991, Recenti progressi in medicina,
W L Sanvito, and J C Villares
[Several physiopathological, clinical & therapeutic aspects of constipation].
November 1958, La Clinica terapeutica,
W L Sanvito, and J C Villares
[Physiopathological, clinical and therapeutic aspects of diabetic coma].
August 1950, Arquivos de clinica,
W L Sanvito, and J C Villares
Physiopathological, clinical and therapeutic aspects of hepatopulmonary syndrome.
January 2010, La Clinica terapeutica,
W L Sanvito, and J C Villares
[Asthma in pregnancy. Physiopathological, clinical, and therapeutic aspects].
December 1993, Minerva medica,
W L Sanvito, and J C Villares
[Amenorrhea; physiopathological and therapeutic aspects].
April 1957, Revista clinica espanola,
Copied contents to your clipboard!